Ambion, Inc. and GE Healthcare have announced that they had entered into a license and supply agreement under which GE Healthcare will manufacture for Ambion microRNA microarrays utilizing GE Healthcare's CodeLink™ Bioarray technology.
These microarrays, the mirVana™ miRNA Bioarrays, include a comprehensive panel of known human, mouse, and rat miRNAs as well as Ambion's proprietary, non-published microRNAs, Ambi-miR™s.
“For years, Ambion has been at the forefront of miRNA research by developing novel tools for isolation, fractionation, detection and expression profiling of miRNA,” said Matt Winkler, Chief Executive Officer of Ambion.
“We are very pleased that this agreement allows Ambion an enhanced ability to provide enabling products and services to researchers involved in the rapidly evolving microRNA research field.”
“This is a great example of how we can take CodeLink's proven technology into new application areas by partnering with companies who are leaders in their field,” said Ger Brophy, vice president of product acquisition and licensing for Discovery Systems, GE Healthcare.
“The combination of CodeLink's array technology with Ambion's content and assays creates an innovative and powerful tool that meets the needs of this growing research market.”